What Caught Our Attention in the Investment World? – Week of February 24-28, 2020

By Kuldip K. Ambastha and Anil K. Ambastha

On Tuesday, February 25, 2020, the stock of Moderna, Inc. (MRNA) rose by 27.8% for the day. As the coronavirus (COVID-19) has spread around the world and led to a sell-off in the capital markets, Moderna, Inc. announced that its coronavirus vaccine candidate is scheduled to be tested in the USA. This biotechnology company’s experimental vaccine has been delivered to the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine, mRNA-1273, is the first vaccine to be tested in the USA on human beings as part of an official Phase 1 clinical trial. Currently, there are no proven health solutions to cure COVID-19 or prevent infection. Several companies are working on vaccines, therapies, and other such items which may help in managing or curing COVID-19. In summary, due to the potential for success with mRNA-1273, Moderna, Inc. was a star performer during this week.

Keywords – Moderna, Inc., Moderna, MRNA, coronavirus, COVID-19, vaccine, mRNA-1273, Phase 1, clinical, trial, USA, biotechnology, biotech, experimental, experiment, National Institute of Allergy and Infectious Diseases, NIAID, health, wellness, infection, therapy.

Disclosure – The principals and clients of Ambastha Financial LLC have no positions in MRNA.

Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2020 – Ambastha Financial LLC.

Leave a Reply

Your email address will not be published. Required fields are marked *